

Reference Number: FOI202324/369
From: Commercial
Date: 10 November 2023
Subject: MRI Scans performed with contrast agent - macrocyclic gadolinium

Q1 The number of MRI scans performed for the following:

- Abdomen, including Liver & Kidneys
- Angiography
- Brain
- Cardiac
- Central Nervous System
- Head & Neck
- Musculo-skeletal system
- Other
- Other Surrounding Tissue
- Pelvis, including Prostate
- Spine
- Thorax, including Breast
- Whole Body

A1

<u>Category</u>	<u>2016/17</u>	<u>2017/18</u>	<u>2018/19</u>	<u>2019/20</u>	<u>2020/21</u>	<u>2021/22</u>
Abdomen, including Liver & Kidneys	34	52	77	95	111	94
Angiography	550	505	542	605	621	707
Brain	2	3	1	1	4	3
Cardiac	3275	3880	4529	4742	4207	5296
Central Nervous System	0	0	0	0	0	0
Head & Neck	77	86	106	97	103	133
Musculo-skeletal system	11	12	10	14	8	5
Pelvis, including Prostate	3	10	13	12	14	1
Spine	55	66	55	53	45	17
Thorax, Including Breast	11	18	16	23	31	82
Whole Body	1	0	0	2	0	41
Other	0	0	0	0	0	0
Other Surrounding Tissue	0	0	0	0	0	0

Q2 The number of MRI scans for the above listed investigations using a macrocyclic gadolinium contrast agent(s)

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to ascertain the data, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

- Q3 The average number of doses of a macrocyclic gadolinium contrast agent(s) per scan
- A3 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to ascertain the data, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q4 The number of rescans, which are performed due to the outcome of a poor-quality image when using a macrocyclic gadolinium contrast agent in the initial scan.
- A4 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to ascertain the data, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q5 The number of rereports required due to the outcome of a poor-quality image when using a macrocyclic gadolinium contrast agent in the initial scan.
- A5 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to ascertain the data, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.